Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

Part of paid clinical trials in San Antonio, Texas.

Sponsor
The University of Texas Health Science Center at San Antonio
Study ID
NCT07470606
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Memantine — DRUG
    The goal dose for Immediate Release Memantine is 10 mg oral twice daily. The goal-dose for Extended-Release Memantine is 21 mg daily.
  • Raloxifene — DRUG
    Raloxifene will be administered at 120mg orally every day

Study Details

The study investigators are testing to see if patients receiving radiation treatment for brain cancer along with raloxifene plus memantidine take longer to develop memory issues. The study will include anyone over the age of 18 who will be treated with radiation for brain cancer.

Key Dates

Start date
Mar 31, 2026
Status verified
Mar 2026
Primary completion
Mar 31, 2030
Completion
Mar 31, 2031

Study Design

Enrollment
108 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Group A: Standard of Care
    Patients will start Memantine as SOC around the time of radiation. Memantine may be continued as SOC as prescribed by the treating physician after the 24 weeks.
  • Experimental: Group B: Standard of Care plus raloxifene
    Patients will start Memantine as SOC around the time of radiation. Memantine may be continued as SOC as prescribed by the treating physician after the 24 weeks. If randomized to group B patients will be recommended to start the assigned Raloxifene at least one week before their anticipated RT treatment start date.

Primary Outcome Measure

Hippocampal volume changes [ Time Frame: Baseline to 48 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mays Cancer Center, UT Health San AntonioSan AntonioTexas78229
Kayla Chamberlain
[email protected]
210-450-5964
Andrew J Brenner, MD, PhD (PRINCIPAL_INVESTIGATOR)
Eva M Galvan, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Antonio, TX

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
Mays Cancer Center, UT Health San Antonio· San Antonio, TX

Related Studies